Medscape Medical NewsAll articles

Kosmos

EchoNous, Inc. • Radiology • 08/06/2021

510(k)IEC 62304 Class C
FDA Summary PDF

Device Purpose

The Kosmos system is a portable diagnostic tool designed for healthcare professionals, integrating ultrasound imaging, electrocardiography, and digital auscultation for comprehensive patient assessment. This iteration expands its clinical utility through the incorporation of new ultrasound modes like Pulsed-Wave and Continuous-Wave Doppler, a linear array transducer for applications such as vascular and musculoskeletal imaging, and additional probe options, all facilitating synchronized data acquisition.

Summary

The Kosmos system is a diagnostic device comprised of a tablet display (either proprietary Kosmos Bridge or a user-supplied Android tablet) and a cabled probe, designed for use by healthcare professionals. Its core functionality integrates ultrasound imaging with electrocardiogram (ECG) and digital auscultation (DA) capabilities, particularly with the Kosmos Torso probe which houses both an ultrasound transducer and sealed microphones, and allows for time-synchronized acquisition of these three data types. The system can operate on battery or mains power and supports Wi-Fi for data management and software updates. The 3-lead single-channel ECG provides a timing reference for the cardiac cycle, enhancing the interpretation of concurrent ultrasound and auscultation data. This iteration of the Kosmos system significantly broadens its diagnostic ultrasound applications and operational modes. Key additions include clinical applications for Vascular/Peripheral Vascular and Musculoskeletal imaging, as well as expanded interventional guidance for procedures such as fluid drainage and nerve blocks. The system now incorporates Pulsed-Wave (PW) Doppler and Continuous-Wave (CW) Doppler modes, alongside new combined modes (B+PW, B+CW). A significant hardware update is the introduction of a linear array transducer (Kosmos Lexsa probe) and ultrasound-only probe variants (Kosmos Torso-One, Kosmos Torso-One USB), complementing the existing phased array transducer. These changes aim to improve diagnostic versatility for adult and pediatric patients in clinical care and medical education settings.

AI Regulatory Concerns

Powered byJev by TypeSafe AI

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

Keywords

Diagnostic UltrasoundElectrocardiograph (ECG)Digital Auscultation (DA)Multimodal DiagnosticsLinear Array TransducerDoppler ImagingInterventional GuidanceVascular AssessmentMusculoskeletal ImagingPortable Ultrasound System

Device Metadata

Submission Number
K212100
Company
EchoNous, Inc.
Panel
Radiology
Product Code
N/A
Data Type
Images
Clinical Function
Assessment
AI Function
Analysis
AI Subclass
quantification/feature localization

Relevant Clinical Questions

  • Q1. How does the time-synchronization of ultrasound, ECG, and digital auscultation enhance diagnostic accuracy or workflow efficiency compared to sequential or separate assessments?; What is the learning curve for healthcare professionals to effectively utilize the expanded ultrasound modes (PW/CW Doppler) and new linear array transducer applications, particularly for interventional guidance?; Are there specific patient populations or clinical scenarios where the integrated digital auscultation offers a distinct advantage over traditional stethoscopes when used alongside real-time ultrasound imaging?; What is the impact of the new probe options (Torso-One, Lexsa) on image quality and diagnostic capabilities across the expanded clinical applications (e.g., musculoskeletal, vascular) compared to the original Kosmos Torso probe?; How does the system's performance, particularly for the newly added Doppler modalities and linear array transducer, compare in terms of sensitivity and specificity to larger, cart-based ultrasound systems in their respective applications?

Risk Classification

ESL Analysis
FDA Device ClassII

FDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement

Learn how Parasoft automates IEC 62304 compliance testing →

Cybersecurity Evidence

Powered by SBOMator™

Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.

Cyber Score25/100
SBOM Evidence⚠ Not mentioned in summary
Cyber Risk Assessment⚠ Not mentioned in summary
Postmarket Plan✓ Detected in Summary
§524B ApplicableNo

Supply Chain BOM Evidence

Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.

SBOMSoftware Bill of Materials
- Not detected
ML-BOMMachine Learning Bill of Materials
- Not detected
SaaSBOMSoftware-as-a-Service Bill of Materials
- Not detected
HBOMHardware Bill of Materials(hardware)
✓ Detected
CBOMCryptography Bill of Materials
- Not detected
VDR/VEXVulnerability Disclosure Report / Vulnerability Exploitability eXchange
- Not detected
OBOMOperations Bill of Materials(operational)
✓ Detected

Analysis:

• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.

• Evidence of HBOM, OBOM detected in AI-generated device summary.

• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.

• Not detected in AI-generated device summary: SBOM, ML-BOM, SaaSBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.

Preparing a similar submission?

ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.

Assess Your Readiness →Or contact ESL directly
Kosmos - EchoNous, Inc. | ESL FDA AI Device Intelligence